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ABSTRACT
The mechanistic target of rapamycin (mTOR) signalling pathway plays a highly 
conserved role in aging; mice lacking ribosomal protein S6 kinase 1 (S6K1-/-) have 
extended lifespan and healthspan relative to wild type (WT) controls. Exactly how 
reduced mTOR signalling induces such effects is unclear, although preservation of 
stem cell function may be important. We show, using gene expression analyses, 
that there was a reduction in expression of cell cycle genes in young (12 week) and 
aged (80 week) S6K1-/- BM-derived c-Kit+ cells when compared to age-matched WT 
mice, suggesting that these cells are more quiescent in S6K1-/- mice. In addition, we 
investigated hematopoietic stem cell (HSC) frequency and function in young and 
aged S6K1-/- and WT mice. Young, but not aged, S6K1-/- mice had more LSK (lineage-, 
c-Kit+, Sca-1+) cells (% of bone marrow (BM)), including the most primitive long-term 
repopulating HSCs (LT-HSC) relative to WT controls. Donor-derived engraftment of LT-
HSCs in recipient mice was unaffected by genotype in young mice, but was enhanced 
in transplants using LT-HSCs derived from aged S6K1-/- mice. Our results are the first 
to provide evidence that age-associated HSC functional decline is ameliorated in a 
long-lived mTOR mutant mouse.
INTRODUCTION
Aging can be slowed and late-life health maintained 
through environmental, genetic and pharmacological 
interventions [1]. The current challenge in aging 
research is to identify exactly how mechanistically 
these interventions act to elicit their beneficial effects, 
and critically whether these mechanisms are conserved 
across different interventions. Stem cell dysfunction 
is a proposed candidate hallmark of aging [2], and it is 
well established that stem cells are critical to cellular 
homeostasis during aging and disease [3]. However, 
stem cells undergo aging-related changes; hematopoietic 
stem cells (HSC) exhibit impaired self-renewal potential, 
stress resistance, engraftment and homing ability during 
aging [3, 4], all associated with immunosenescence, 
myelo-proliferative and autoimmune disease [5]. Several 
studies have investigated whether stem cell function 
during aging is slowed in long-lived animal models. In 
male Drosophila, dietary restriction(DR) attenuated an 
age-related loss of germline stem cells [6], and increased 
HSC number and function in aged mice [7, 8]. DR also 
increased HSC quiescence and enhanced repopulating 
capacity in 12 months old mice relative to ad libitum fed 
controls [9]. Similarly, very small embryonic-like stem 
cell number was increased in long-lived growth hormone 
deficient mice, compared to age-matched controls [10]. 
However, progenitor cells and HSCs have not been fully 
characterised in other genetic mouse models of longevity 
[3]; if stem cell dysfunction is an important driver of 
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organismal aging [2], then one might predict that their 
function during aging would be preserved in long-lived 
mutants relative to control mice.
It is well established that hyperactivation of the 
mTOR signalling pathway can induce premature aging 
within HSCs [3, 11-13] and that activity of various 
components of the mTOR signalling pathway is increased 
within HSCs of aged mice [13]. In addition, rapamycin, 
which acts to inhibit the mTOR pathway, both extends 
lifespan in model organisms [14-16] and restores self-
renewal capacity, hematopoiesis, ex vivo expansion 
and long-term reconstitution in aged murine HSCs [11, 
13]. Similarly, rapamycin treatment restored autophagy 
activity in aged skeletal muscle satellite cells, attenuated 
senescence and increase expansion of aged satellite cells 
following engraftment [17]. We have previously reported 
that mice which are globally null for ribosomal protein 
S6 kinase 1 (S6K1-/-), a key downstream effector of 
mTOR [18], are long-lived and show extended healthspan 
relative to wild-type (WT) controls mice, including the 
preservation of naïve T-cell relative to memory T-cell 
subsets during aging [19]. Consequently, we predicted 
that HSC function would be enhanced in long-lived S6K1-/- 
mice relative to WT controls during aging. In order to test 
this prediction, we characterised gene expression profiles 
in isolated bone marrow (BM) c-Kit+ cells (HSCs and 
progenitor cells) of a number of candidate genes that have 
previously been linked to HSC function and maintenance 
[20-27], or whose expression has been shown to be altered 
within HSCs through modulation of the mTOR signalling 
pathway [11, 28]. Secondly, we investigated HSC function 
following transplantation challenge in young (12 weeks 
of age) and aged (80 weeks of age) WT control and S6K1-
/- mice. 
RESULTS
To gain some potential insight in to how the absence 
of S6K1 may impact on stem cell function during aging, 
we isolated BM c-Kit+ cells (HSCs and progenitor cells) 
from young and aged WT and S6K1-/- mice and undertook 
gene expression profiling of candidate genes linked to 
HSC function and maintenance (Table S1 & S2). Using 
a multivariate approach, we identified several genes 
significantly affected by genotype, by age or that showed 
an interaction between both (Table S1). The mRNA 
Figure 1: Gene expression levels of candidate genes within bone marrow derived c-Kit+ cells linked to HSC aging 
and function in young and aged WT and S6K1-/- mice. Graphs show a significant genotype A.-D., age E.-K. or both a significant 
genotype and an age effect L.. A significant interaction between genotype and age was observed for both S6K2 J. and Irs1 L.. Graphs 
display mean (±SEM) fold-change, all relative to the young WT group (female mice, n = 3-5; genotype effects * P < 0.05, age effects # P 
< 0.05, ## P < 0.01), with closed bars indicating WT mice and open bars indicating S6K1-/- mice. See also Tables S1 and S2. 
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expression levels of Ccnd1, Ccnd2, Rb1, Atf4 and Irs1 
were all significantly reduced in S6K1-/- mice (Figure 1A-
1D, 1L, Table S1), with age affecting the expression of 
Cdkn2a, Cdkn1b, Ezh2, Atg7, Bcl2, S6K2, Xbp1 and Irs1 
(Figure 1E-1K, 1L, Table S1). Only S6K2 and Irs1 showed 
a significant interaction between genotype and age, with 
the age-associated decrease in expression of both more 
pronounced in WT mice than in S6K1-/- mice. 
No genotype effects were detected in the cellularity 
of bone marrow (BM), spleen or thymus or in mature cell 
frequencies in BM of young mice (Figure S1A-S1D). 
Young S6K1-/- mice showed a greater frequency of stem/
progenitors (LSK, lineage-, c-Kit+, Sca-1+) within BM 
compared to WT mice (Figure 2A). Young S6K1-/- mice 
also showed higher frequencies of long-term repopulating 
HSC (LT-HSC) (LSK, CD150+, CD48-), hematopoietic 
progenitor cells (HPC-1) (LSK, CD150-, CD48+) and 
multipotent progenitors (MPP) (LSK, CD150-, CD48-) in 
comparison to WT controls (Figure 2B). No difference in 
chimerism between genotypes (Figure 2C) was observed 
following transplantation of young female WT or S6K1-
/- LT-HSC (CD45.2+) into irradiated recipients (CD45.1+), 
although a non-significant trend for an increase in 
percentage chimerism following transplantation with 
S6K1-/- LT-HSC cells was observed (p = 0.088). However, 
donor derived cell contribution indicated that S6K1-/- LT-
HSC skewed mature cell frequency, with more T lymphoid 
cells at 16 weeks post transplantation (Figure S2A-S2E). 
In aged mice, genotype did not affect BM, spleen or 
thymus cellularity, or the frequency of BM mature cell 
Figure 2: HSC frequency and function in young and aged WT and S6K1-/- mice. A. LSK frequency (percentage of total BM), 
B. frequency (percentage of total BM) of LT-HSC, HPC-1, HPC-2 and MPP in young WT and S6K1-/- mice (n = 9-11, mixed gender). C. 
Percentage of chimerism (CD45.2+ cells) in peripheral blood (PB) from irradiated recipients transplanted with young WT or S6K1-/- LT-
HSCs (donor cells female, recipients mixed gender, n = 6-9). The effect of genotype on chimerism was non-significant (F = 3.037, P = 
0.088), although the effect of time was (F = 5.696, P = 0.002). D. LSK frequency and E. frequency of LT-HSC, HPC-1, HPC-2 and MPP 
in BM of aged WT and S6K1-/- mice (n = 7-15, mixed gender). F. Percentage of chimerism (CD45.2+ cells) in PB from irradiated recipients 
transplanted with aged WT or S6K1-/- LT-HSCs (donor cells female, recipients mixed gender, n = 6). A highly significant genotype effect 
was detected (F = 8.452, P = 0.006), but the effect of time was non-significant (F = 0.494, P = 0.688). (* P < 0.05, ** P < 0.01, *** P < 
0.001). Values are mean±SEM, with closed bars indicating WT mice and open bars indicating S6K1-/- mice.
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types (Figure S3A-S3D). Similarly, the frequency of LSK 
cells, or HSC sub-populations within these LSK cells were 
unaffected by genotype (Figure 2D and 2E). However, 
following transplantation a greater percentage chimerism 
in mice transplanted with S6K1-/- LT-HSC cells (Figure 
2F), strongly suggestive that HSC function was preserved 
during aging in S6K1-/- mice relative to WT controls. 
No genotypic difference in donor-derived mature cells 
within the BM of recipient mice was observed following 
transplantation (Figure S4A-S4D). 
DISCUSSION
Our preliminary findings in c-Kit+ cells indicate a 
significant reduction in the expression of Ccnd1and Ccnd2 
in S6K1-/- mice; genes that encode the G-1 phase regulators 
Cyclin D1 and 2. These findings suggest that reduced TOR 
signalling may be associated with greater quiescence 
within this cell population, as reported elsewhere 
[29]. Thus, genetic deletion of S6K1 may suppress 
geroconversion, that is a switch from reversible cell cycle 
arrest to senescence [30, 31], within HSCs during aging. 
Interestingly HSC quiescence has also been observed in 
mice following DR [9], suggesting that HSC quiescence 
may be a shared characteristic of different mouse models 
of slowed aging. However, it should be noted that the 
BM cells used in our study contained both HSCs and 
progenitor cells, and so an important next step will be 
to examine transcriptional changes solely within HSCs. 
Interestingly, the expression levels of insulin receptor 
substrate 1 (Irs1) was significantly lower in S6K1-/- cells 
relative to WT cells (Figure 2L). IRS1 is a key adaptor 
protein within the insulin/IGF-1 signalling pathway, and 
we have previously reported that Irs1-/- mice have extended 
lifespan and healthspan relative to WT mice [32]. Whether 
preserved HSC function is a conserved phenotype that is 
found across different long-lived genetic mutant mice 
has yet to be established. We observed no age-associated 
increase in either erythropoiesis or myelopoiesis in BM 
of young or aged S6K1-/- mice, in contrast to what has 
been reported in DR mice [9]. In line with our original 
prediction, HSCs derived from aged female S6K1-/- mice 
showed a greater percentage engraftment following 
transplantation, in line with studies examining HSC 
function in aged mice following rapamycin treatment [11, 
13]. Importantly, no difference in engraftment, relative to 
WT mice, was observed when HSCs from young S6K1-/- 
mice were transplanted in to irradiated hosts, suggesting 
that the loss of S6K1 specifically slowed an age-associated 
deterioration in HSC function. The findings of this study 
provide compelling evidence that the functional decline 
of HSCs during aging is ameliorated in long-lived mTOR 
mutant mice. Consequently, these observations further 
underscore the potential importance of mTOR signalling 
to HSC aging, and may provide new insights into the 
potential linkage between HSC ageing and organismal 
lifespan and healthspan [13, 28, 29, 33]. The clear 
challenge now following on from these initial findings 
is to now fully characterise HSCs from these mice in 
order to help identify the mechanisms underpinning the 
observed preservation of HSC function during aging. For 
example, a critical next experiment will be to investigate 
engraftment following transplantation of male-derived 
S6K1-/- LT-HSCs; male S6K1-/- mice show evidence of 
extended healthspan but are not long-lived relative to male 
WT mice [19]. 
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board. All procedures followed the 
1986 UK Home Office Animals Procedures Act (PPL: 
60/4492 and 70/7438).
S6K1 wild-type (WT) and S6K1 global null (S6K1-
/-) mice were bred and maintained following previously 
described protocols [19, 34]. B6SJL mice expressing 
CD45.1 were bred and maintained according to standard 
procedures (Beatson Institute for Cancer Research, 
Glasgow, UK). WT and S6K1-/- animals were fasted 
overnight and culled by cervical dislocation. Blood was 
harvested in EDTA treated tubes (Sarstedt AG & Co, 
Germany) and leg bones (femur and tibia), spleen and 
thymus were harvested in PBS supplemented with 2% 
FBS (PBS/2%FBS) on ice. Mice were culled at either 12 
weeks (12.86±0.07 wks; referred to as young in text) or 80 
weeks of age (82.83±0.71 wks; referred to as aged in text). 
B6SJL mice were used for the transplantation assays at 10 
weeks of age (10±0.50 wks). 
Bones were subsequently crushed using a pestle and 
mortar in PBS/2%FBS and spleen/thymus were mashed 
using a 5mL syringe in a petri dish and all cell suspensions 
were filtered through a 70µm mesh in PBS/2%FBS. 
Cellularity was assessed in bone marrow (BM), spleen and 
thymus cells using an automated cell counter. Briefly, the 
number of cells was quantified using the Guava ViaCount 
reagent using a 1:10 dilution and the Guava easyCyte 
flow cytometer (Millipore UK Ltd, Hertfordshire, UK). 
Cellularity per mL was multiplied by the total volume of 
cell suspension to get the absolute number of white blood 
cells (WBC) per harvest. 
BM, spleen and thymus cell suspensions were spun 
in a flow cytometry (FACS) tube at 400xg for 5 min with 
1x105 or 1x106 cells and incubated with Fc block for 5 min 
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on ice (excluding cells stained with an antibody against 
CD16/CD32). Cells were subsequently stained with cell 
surface markers in PBS/2%FBS and incubated on ice for 
20 min before washed in PBS/2%FBS. Cells stained with 
antibodies against biotin were subsequently stained with 
streptavidin, incubated for 20 min on ice and washed in 
PBS/2%FBS before FACS analysis. Blood samples were 
incubated with the antibody mix for 20 min at room 
temperature (RT) with subsequent addition of red blood 
cell (RBC) lysis buffer (Dako UK Ltd, Cambridgeshire, 
UK) as per the manufacturer’s protocol. After 10 min 
at RT in the lysis buffer, FACS analysis was carried out 
immediately. Cell surface antibodies were purchased from 
BD Biosciences (Oxford, UK), eBioscience Ltd (Hatfield, 
UK) or BioLegend (London, UK) unless otherwise stated. 
Antibodies used were against Gr-1, CD11-b, CD19, Ter-
119, CD4, CD8a, CD44, CD45RB, CD5, B220, c-Kit, 
Sca-1, CD150, CD48, CD16/32, CD127 and CD34. FACS 
analysis was carried out using a LSRII, FACS Canto II and 
cells were sorted using a FACS Aria (BD Biosciences). 
FACS analysis was carried out using FlowJo software 
(Ashland, OR, USA) using unstained and single colour 
controls. All gating strategies used are displayed (Figure 
S5). 
B6SJL mice were irradiated with 7Gy 24 hours prior 
to transplant. Mice were treated with Baytril for 2 weeks 
post-transplant. 100 LT-HSC (Lineage-, c-Kit+, Sca-1+, 
CD150+, CD48-) from donor mice (CD45.2+) were sorted 
into a cell suspension of CD45.1+ support BM (200,000 
cells) for intravenous injection per irradiated recipient 
mouse. Animals were bled every 4 weeks post-transplant 
to assess chimerism using FACS. After 16 weeks post-
transplant, animals were culled and BM harvested to 
examine chimerism. Chimerism was assessed using the 
percentage of donor derived cells (CD45.2+) in the PB 
and BM of recipient mice. If the percentage chimerism 
was < 1% in the peripheral blood then we assumed 
failed engraftment and this data was excluded from 
all subsequent analysis (See Figure S6 for a schematic 
representation of the experiment).
c-Kit+ cells from BM were isolated using positive 
microbead separation (Miltenyi Biotec Ltd, Surrey, 
UK). After isolation, RNA was extracted (Qiagen Ltd, 
Manchester, UK) and RNA concentration and quality 
assessed using a NanoDrop and Agilent bioanalyser 
(Agilent technologies LDA Ltd, Cheshire, UK). Total RNA 
(290ng) from each sample was synthesised into cDNA 
(Life Technologies Ltd, Paisley, UK) and subsequently 
pre-amplified using Taqman™ pre-amplification master 
mix with Taqman™ probes of interest and protocol 
according to standard procedures. Pre-amplified cDNA 
was run on a 48.48 Fluidigm chip as per standard 
procedures (Fluidigm UK Ltd, Cambridge, UK) and data 
analysed using biomark software (Fluidigm UK Ltd). The 
ΔΔCT method was used to assess differences between 
groups using the WT young group as the calibrator. 
Taqman probes with assay ID mentioned in this study can 
be viewed in Table S1.
Data was analysed using GraphPad Prism version 
6.00 (GraphPad Software, La Jolla Ca, USA, www.
graphpad.com) and SPSS version 22 (SPSS Inc., Chicago, 
Il, USA). Student’s unpaired t-test and general linear 
models (GLM) were used to assess statistically significant 
differences between groups. 
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